CERAMENT® BONE VOID FILLER RECEIVES FDA CLEARANCE FOR SPINAL INTERBODY FUSION PROCEDURES

Published: 2024-03-05

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, announces that the company’s 510 (k) submission for CERAMENT BONE VOID FILLER to include Spine Interbody Fusion procedure has been cleared by the FDA. As previously informed, a market introduction in the spine segment could take place at the end of 2025.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-05 20:35 CET.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

CERAMENT® BONE VOID FILLER RECEIVES FDA CLEARANCE FOR SPINAL INTERBODY FUSION PROCEDURES